Log In Get Started
Press Releases April 29, 2026 08:05 PM

Vaccinex Reports 2025 Annual Financial Results

Vaccinex Reports 2025 Annual Financial Results Highlighting Progress in Neurodegenerative Diseases and Cancer Therapeutics

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
VCNX

Vaccinex, Inc., a clinical-stage biotechnology company focused on developing novel antibody therapies for Alzheimer’s, Huntington’s disease, and cancer, released its financial results for 2025. The company is advancing its pipeline with plans to initiate a Phase 2b study in Alzheimer's disease, demonstrating ongoing commitment to addressing serious diseases with unmet medical needs.

Vaccinex Reports 2025 Annual Financial Results
VCNX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Vaccinex is pioneering novel investigational antibody therapies targeting neurodegenerative diseases and cancer.
  • The company released its 2025 financial results, with details posted on its website.
  • Vaccinex is initiating a new Phase 2b clinical trial in Alzheimer’s disease, signaling pipeline progress.

ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website.

About Vaccinex, Inc.

Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders, and is currently initiating a new Phase 2b study in Alzheimer’s disease. Vaccinex is based in Rochester, New York.

Investor Contact
Elizabeth Evans, PhD
Chief Operating Officer, Vaccinex, Inc.
(585) 271-2700
eevans@vaccinex.com


Risks

  • As a clinical-stage biotech company, Vaccinex faces risks related to clinical trial outcomes and regulatory approvals.
  • Financial performance details, while released, were not highlighted, suggesting potential uncertainties in revenue and funding.
  • The biotechnology sector remains volatile, with investments dependent on successful product development and market acceptance.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026